m+Medelevator.RU
← Поиск публикаций
Nature biomedical engineering · 2024

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Rezaei Reza, Boulton Stephen, Ahmadi Mahsa, Petryk Julia, Da Silva Miles, Kooshki Zamani Nika, Singaravelu Ragunath, St-Laurent Gabriel, Daniel Lauren, Sadeghipour Arezoo, Pelin Adrian, Poutou Joanna, Munoz Zuniga Abril Ixchel, Choy Clarence, Gilchrist Victoria H, Khalid Zumama, Austin Bradley, Onsu Kemal Alper, Marius Ricardo, Ameli Zahra, Mohammadi Fazel, Mancinelli Valeria, Wang Emily, Nik-Akhtar Abolfazl, Alwithenani Akram, Panahi Arasi Fatemeh, Ferguson Stephen S G, Hobman Tom C, Alain Tommy, Tai Lee-Hwa, Ilkow Carolina S, Diallo Jean-Simon, Bell John C, Azad Taha

Аннотация

Optimization of oncolytic viruses for therapeutic applications requires the strategic removal or mutagenesis of virulence genes alongside the insertion of transgenes that enhance viral replication, spread and immunogenicity. However, the complexity of many viral genomes and the labour-intensive nature of methods for the generation and isolation of recombinant viruses have hindered the development of therapeutic oncolytic viruses. Here we report an iterative strategy that exploits the preferential susceptibility of viruses to certain antibiotics to accelerate the engineering of the genomes of oncolytic viruses for the insertion of immunomodulatory cytokine transgenes, and the identification of dispensable genes with regard to replication of the recombinant oncolytic viruses in tumour cells. We applied the strategy by leveraging insertional mutagenesis via the Sleeping Beauty transposon system, combined with long-read nanopore sequencing, to generate libraries of herpes simplex virus type 1 and vaccinia virus, identifying stable transgene insertion sites and gene deletions that enhance the safety and efficacy of the viruses.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты